External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>The US sales stood at $177 Mn (+11% YoY) and the growth was supported by flu season, and new launches such as gSuprep, gPerforomist, Pennsaid, and Brovana, among others.</li><li>The base business fell by a high single digit due to price erosion.</li><li>India Sales were muted at 3.3% YoY and have been impacted by the loss in Cidmus and the generalization of Sitagliptin.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

The US sales stood at $177 Mn (+11% YoY) and the growth was supported by flu season, and new launches such as gSuprep, gPerforomist, Pennsaid, and Brovana, among others.The base business fell by a high single digit due to price erosion.India Sales were muted at 3.3% YoY and have been impacted by the loss in Cidmus and the generalization of Sitagliptin.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

LUPIN Ltd - Margins Still Below Industry Levels

Lupin Ltd

LUPIN Ltd - Margins Still Below Industry Levels